廣告
香港股市 已收市

  • 恒指

    17,769.14
    +50.53 (+0.29%)
     

  • 國指

    6,374.91
    +43.05 (+0.68%)
     

  • 上證綜指

    2,997.01
    +2.28 (+0.08%)
     

  • 道指

    39,169.52
    +50.66 (+0.13%)
     

  • 標普 500

    5,475.09
    +14.61 (+0.27%)
     

  • 納指

    17,879.30
    +146.70 (+0.83%)
     

  • Vix指數

    12.69
    +0.47 (+3.85%)
     

  • 富時100

    8,131.98
    -34.78 (-0.43%)
     

  • 紐約期油

    83.90
    +0.52 (+0.62%)
     

  • 金價

    2,338.50
    -0.40 (-0.02%)
     

  • 美元

    7.8130
    +0.0012 (+0.02%)
     

  • 人民幣

    0.9302
    +0.0004 (+0.04%)
     

  • 日圓

    0.0481
    -0.0000 (-0.08%)
     

  • 歐元

    8.3746
    -0.0121 (-0.14%)
     

  • Bitcoin

    62,641.31
    -204.34 (-0.33%)
     

  • CMC Crypto 200

    1,339.28
    -5.22 (-0.39%)
     

Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings

Zacks Equity Research
·2 分鐘文章

For the quarter ended March 2024, NeoGenomics (NEO) reported revenue of $156.24 million, up 13.9% over the same period last year. EPS came in at -$0.02, compared to -$0.09 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $149.82 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.03.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

廣告

Here is how NeoGenomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Clinical - Number of tests performed: 300,827 compared to the 296,176 average estimate based on three analysts.

  • Clinical - Average revenue/test: $0.45 compared to the $0.43 average estimate based on three analysts.

  • Revenue- Advanced Diagnostics: $21.71 million versus $21.79 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.9% change.

  • Revenue- Clinical Services: $134.54 million versus the four-analyst average estimate of $128.18 million. The reported number represents a year-over-year change of +17.1%.

View all Key Company Metrics for NeoGenomics here>>>

Shares of NeoGenomics have returned -1.1% over the past month versus the Zacks S&P 500 composite's -2.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NeoGenomics, Inc. (NEO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research